Evidence-based medicine (Ebm) is not ar andomised controlled trial (rct), but Ebm seeks to apply evidence gained from scientific methods -which could be rct -todaily medical practice. any surgical treatment reflects ac ertain development technically as well as skills based. the procedure may be modified and refined and the device may be developed and inherent technical weaknesses may need to be corrected. therefore the best time to conduct atrial may be discussed. the appropriate time to initiate arct is when all the participating surgeons or therapists have gone through their learning curve. special considerations should be given in rapidly developing fields. if started too early the resulting comparison will likely turn out to be irrelevant because the new technology is not fully developed, not mastered or the device may have undergone major modifications rendering the results obsolete. on the other hand, if started too late there is a chance that data may be lost because the technology has already been introduced into the daily clinics and physicians may be unwilling to recruit patients. or the opposite, that the technique may have been rejected without aproper trial. in this situation it has been suggested to perform asocalled tracker trial. in such trials protocols are more flexible without prefixed sample size and will require repeated interim analyses. often, it will be relevant to supplement the clinical trials with data from large clinical databases -inparticular when long term results are needed.
the concepts behinde vidence-based practice.T he methods used to determine "best evidence" wereintroduced by David Sackett and the McMaster University (3). The term "evidence-based" is less than 20 years old and the term "evidence-based medicine" first appeared in the medical literaturein1992 (4). A MedLine search of the term in 1993 revealed 6c itations, last year 24,692 and today 29,021 (5).
DEFiniTion AnD LEVELS oF EViDEnCE
Evidence-based medicine (EBM) is not arandomised controlled trial (RCT) (5), but EBM seeks to apply evidence gained from scientific methods -w hich could be RCT -t od aily medical practice. it tries to BACKgRoUnD Though medical interventions have been tested during centuries, it first evolved to impact health carein the 20th century (1). Archie Cochrane, whose name is immortalised through the Cochrane Collaboration (2), has been credited for an increasing acceptance of assess the solidity of the evidence taking risks and benefits of treatments or no treatment into account (1). The "official" definition sounds "Evidence-based medicine is the conscientious, explicit and judicious use of current best evidence in making decisions about the careofindividual patients" (3, 5, 6). it integrates the best external evidence with the doctor's clinical expertise and the patient's choice during the clinical decision making process.
The validity of any study depends on anumber of issues, such as the cohort of patients studied, the research question investigated, the defined outcomes, thepower calculations, the completeness of data, the potential generalisability of the results and more(7). For convenience studiesare categorisedaccording to study design and methodology.T he strongest evidence is based on RCT,i np articular if several RCTs areathand for asystematic review.inthe other end of the spectrum we find case reports and expert opinion, which have limited value as proof because of placebo effect, bias and more. one such categorisation is shown in Tables 1and 2.
Basics for practising EBM is the asking of focused and unambiguous questions, which must be clinically relevant to patients' problems and phrased to direct your search to give precise answers (6). in practice, questions usually contain the four elements of the PiCo structure: p atient or Problem, i ntervention, c omparison interventions and o utcomes (6), e.g. "in patients with AAA >6cmindiameter,would EVAR -w hen compared to open surgery -l ead to lower mortality?"
RAnDoMiSED ConTRoLLED TRiAL (RCT)
RCTsare considered the gold standardofclinical investigation and should be used whenever possible to provide best evidence for change of practice. The first trials sought huge treatment effects and could thereforeb er elatively small. Later,a st rials investigated smaller treatment effects or preventive interventions with low event rates, substantially larger trials were needed. Also, thereh as been am arked change from small RCTsi nvestigating surrogate endpoints towards large straight forwardt rials addressing hard endpoints such as death and stroke. Though RCTsare considered best basis for establishing solid evidence, it must be realised that RCTsare not equal, and that the likelihood that aRCT reflects the truth will vary with methodological issues and sample size (8). Moreover,"best evidence" is frequently based on less superior data than those generated from RCTs EViDEnCE in SURgERy one major problem in practicing EBM in surgical conditions is the relative lack of good evidence. Surgical options such as minimally invasive procedures may have been adopted without the benefit of good quality randomised trials, as occurred with laparoscopic cholecystectomies and in video-assisted thorascopic sympathectomy.However,the majority of new surgical procedures requireassessment, for example, carotid stenting versus endarterectomy,orembolisation of intracranial aneurysm versus microsurgical clipping. organising good RCTsf or surgical procedures is challenging and there are a few peculiarities when compared with traditional RCTsfor new drugs. Clinical trials arecomplicated and designs involve a number of trade-offs (9, 10).
Lilforde ta lh ave reviewed some of the common problems encountered in surgical studies such as blinding, dependence of results on technical skills and continued evolution of technology (7). Modern surgery has developed primarily by the application of new technology in addition to new forms of imaging and reliable, safe anaesthesia, as well as improved perioperative care-have resulted in progressive improvements over decades. generally few advances in surgery have been made by learning from the results of RCTs,t hough therea re some exceptions particularly in vascular surgery.S urgical research has been criticized for using weak methodology because fewer RCTsand morecases series aregenerally used for the advancement of surgical techniques (10) . over the last decades surgical RCTsh ave become morec ommon. The critique of surgical trials may not be justified, as arecent review of the reported quality of trials in operative surgery found they werenodifferent from nonsurgical trials published in high-profile peer (13) . With objective outcomess uch as death,a mputation or stroke the lack of blinding will not influence interpretation (8). By not blinding the person, who enrols patients into at rial regarding which treatment the patient is allocated to, also induces bias. This may be the case in non randomised trials. Especially,ifdifferences between treatments arem odest, bias may distort the whole picture. no randomisation, no blinding, as well as exclusion of certain patients, will induce bias, and most likely lead to an overestimation of the treatment effect. it has been estimated that only about 50% of clinical situations area menable to randomiseds tudies (14) . Therea re of course many situations in which a randomised study is not required to answer aq uestion. For example, it is not necessary to do ar andomised study to assess whether parachute use can prevent death and major trauma related to jumping from aircrafts (15) .
TiMing
Any surgical treatment reflects acertain development technically as well as skills based and the procedure may be modified and refined and the device may be developed and inherent technical weaknesses may need to be corrected. Thereforethe best time to conduct atrial may be discussed.
intuitively,t he appropriate time to initiate aR CT is when all the participating surgeons or therapists have gone through their learning curve, and that the trial could be completed within 1-2 years, beforea new technique has evolved. Surgeons would generally be reluctant to randomise until they become proficient in atechnique (16) . Aquestion then is whether early experience should be included in atrial or specifically excluded. in many trials only physicians who have gained experience based on aprespecified number,f or instance 10-30, can take part. Conversely,a trial to test atechnique in which they do not believe may be initiated at the stage when the technique has not yet been mastered. Awell known example is the Leicester trial that compared carotid endarterectomy with carotid angioplasty (17) .
Special considerations should be given in rapidly developing fields (7). if started too early the resulting comparison will likely turn out to be irrelevant because the new technology is not fully developed or not mastered or the device may have undergone major modifications rendering the results obsolete. if started too late, however,thereisachance that data may be lost because the technology has already been introduced into the daily clinics and physicians may be unwilling to recruit patients. or the opposite, that the technique may have been rejected without a proper trial. Moreover,itmay be considered unethical to include patients if it is perceived -f air or not -that the new technology is superior.inthis situation it has been suggested to perform as oc alled tracker trial. These include arandomised comparison of two generict echnologies and an observational study of the differences within these broad types of treatments.The endovascular aneurysm repair trials were based on this concept (18) (19) (20) . in such trials protocols arem orefl exible without prefixed sample size and will requirerepeated interim analyses.
oTHER LiMiTATionS WiTH RCTS Randomised trials areg enerally unable to predict what happens in sub-groups as sub-group analysis does not always allow the important features from these groups to emerge (12) .
Exclusion criteria leave out many patients who in clinical practice need to have treatment (12) . Results of aR CT cannot be extrapolated to those patients. not uncommonly,aRCT only include 10% or less of the eligible patients, which further limits the generalisability of atrial. Another reasonthat may limit the applicability is because trial data have been generated from extremely talented therapists with proven low complication rates. Also, treatment effectiveness reported from clinical studies may be higher than that achieved in later routine clinical practice due to the closer patient monitoring during trials that leads to much higher compliance rates.
it is difficult to make suret hat each patient, particularly in multicentret rials, is having similar concomitant therapy.
Some trials areo fi nadequate duration or are stopped prematurely.RCTsstopped early for benefit, often fail to report relevant information adequately about the decision to stop early,and show implausibly large treatment effects, particularly when the number of events is small (21) . These findings suggest clinicians should view the results of such trials with scepticism.
REgiSTRiES
often, it will be relevant to supplement the clinical trials with data from large clinical databases -inpar-ticular when long term results areneeded. As endovascular aortic aneurysm repair becomes increasingly accepted, it will become difficult to use RCTs. Even in situations when an RCT may be appropriate, time for planning and costs areo bstacles. Moreover,a s mentioned above, EVAR is adeveloping technology -the target is moving, i.e. the devices used in an RCT may no longer be available at the time the results become known. For such situations registries may provide useful information, though the limitations must be recognized (22) . Data collection may neither be comprehensive nor complete, thus representing a biased view of the technology and its performance. Censoring may be unintentional, but one must expect that it can also be intentional. For instance only the most clear-cut and successful cases may be entered into the database, complications may be lost in transition, and follow-up data may be impossible to retrieve. An inherent problem with new techniques is that the relevant population may not be clearly defined and patients included in one centremay be unrecognisable in other centres. Also in this situation when the indications arel ess well defined pressure from customers may affect the case-mix. Therefore, it is important that conclusions drawn from registries areinterpreted cautiously.
in general, multicenter studies and national surveys report higher incidences, i.e. morec orrect figures, of mortality and complications than single-centres tudies. in assessments of smaller numbers of patients, those with significant risk factors or even slightly adverse anatomy may be excluded from participation. in addition, reporting methods areperhaps less rigorously checked. Vascular registries may also reflect existing general practise patterns better than some of the controlled studies. given the need for accurate long-term data and the resources required to maintain and validate these, therem ust be concerns that these will fail to provide adequate data, because the registries arev oluntary.F or effective benchmarking this is not good enough. Data collection needs to be both comprehensive and complete, i.e. all centres undertaking EVAR should be required to submit all relevant data on all eligible patients. Compulsory data submission is not au niversally popular concept and is difficult to enforce. However, it is in the interests of national healthcaresystems to ensurethat all EVAR data arecollected and analysed and perhaps other countries could follow the Belgian example by making verifiable data submission aprerequisite for reimbursement of the procedure. Thus, while therea re good arguments in favour of using dedicated vascular registries to monitor European EVAR activity,itisimportant to understand the limitations of registry data, first of all related to the incomplete and biased natureofthe data set [ (22) . oTHER LiMiTATionS in MAKing THE EViDEnCE AVA iLABLE it is recognised that not all evidence is made accessible, that this can limit the effectiveness of any approach, and that effort to reduce various publication and retrieval biases is required.
Failuretopublish negative trials is the most obvious gap, and moves to register all trials at the outset, and then to pursue their results, have now been implemented (23) (24) (25) . Changes in publication methods, particularly related to the Web, should reduce the difficulty of obtaining publication for ap aper on a trial that concludes it did not prove anything new, including its starting hypothesis.
Therei sag ap between best practice and actual clinical care. Studies in US and Europe suggest that up to 50% of patients do not receive careaccording to current scientific evidence (26, 27) . Various initiatives have been suggested to bridge this gap (28) .
